Tearsheet
EKSO Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About EKSO Interactive Breakdown Better Bets vs. EKSO Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Trade Sentinel Industry Resource Links External Quote Links

Ekso Bionics (EKSO)

Market Price (5/2/2026): $12.0 | Market Cap: $42.8 Mil
Sector: Health Care | Industry: Health Care Equipment

Ekso Bionics (EKSO)

Market Price (5/2/2026): $12.0
Market Cap: $42.8 Mil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, Automation & Robotics, and Digital Health & Telemedicine. Themes include Geriatric Care, Show more.

Weak multi-year price returns
2Y Excs Rtn is -79%, 3Y Excs Rtn is -122%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -16 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -134%

Stock price has recently run up significantly
6M Rtn6 month market price return is 119%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -34%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.1%, Rev Chg QQuarterly Revenue Change % is -37%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13%

Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -103%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -105%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 68%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -42%

High stock price volatility
Vol 12M is 1455%

Key risks
EKSO key risks include [1] its consistent history of significant losses and [2] a high probability of future financial distress.

0 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, Automation & Robotics, and Digital Health & Telemedicine. Themes include Geriatric Care, Show more.
1 Weak multi-year price returns
2Y Excs Rtn is -79%, 3Y Excs Rtn is -122%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -16 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -134%
3 Stock price has recently run up significantly
6M Rtn6 month market price return is 119%
4 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -34%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.1%, Rev Chg QQuarterly Revenue Change % is -37%
5 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 13%
6 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -103%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -105%
7 Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 68%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -42%
9 High stock price volatility
Vol 12M is 1455%
10 Key risks
EKSO key risks include [1] its consistent history of significant losses and [2] a high probability of future financial distress.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 35.5% change in EKSO stock from 1/31/2026 to 5/1/2026 was primarily driven by a 135.4% change in the company's P/S Multiple.
(LTM values as of)13120265012026Change
Stock Price ($)8.7011.7935.5%
Change Contribution By: 
Total Revenues ($ Mil)1512-21.6%
P/S Multiple1.53.6135.4%
Shares Outstanding (Mil)34-26.6%
Cumulative Contribution35.5%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/1/2026
ReturnCorrelation
EKSO35.5% 
Market (SPY)3.6%27.4%
Sector (XLV)-5.8%26.5%

Fundamental Drivers

The 118.7% change in EKSO stock from 10/31/2025 to 5/1/2026 was primarily driven by a 279.9% change in the company's P/S Multiple.
(LTM values as of)103120255012026Change
Stock Price ($)5.3911.79118.7%
Change Contribution By: 
Total Revenues ($ Mil)1512-21.6%
P/S Multiple1.03.6279.9%
Shares Outstanding (Mil)34-26.6%
Cumulative Contribution118.7%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/1/2026
ReturnCorrelation
EKSO118.7% 
Market (SPY)5.5%17.8%
Sector (XLV)1.5%10.0%

Fundamental Drivers

The 65.8% change in EKSO stock from 4/30/2025 to 5/1/2026 was primarily driven by a 457.0% change in the company's P/S Multiple.
(LTM values as of)43020255012026Change
Stock Price ($)7.1111.7965.8%
Change Contribution By: 
Total Revenues ($ Mil)1812-35.5%
P/S Multiple0.73.6457.0%
Shares Outstanding (Mil)24-53.9%
Cumulative Contribution65.8%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2025 to 5/1/2026
ReturnCorrelation
EKSO65.8% 
Market (SPY)30.4%4.3%
Sector (XLV)5.2%0.4%

Fundamental Drivers

The -47.2% change in EKSO stock from 4/30/2023 to 5/1/2026 was primarily driven by a -75.1% change in the company's Shares Outstanding (Mil).
(LTM values as of)43020235012026Change
Stock Price ($)22.3511.79-47.2%
Change Contribution By: 
Total Revenues ($ Mil)1412-20.1%
P/S Multiple1.43.6165.2%
Shares Outstanding (Mil)14-75.1%
Cumulative Contribution-47.2%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2023 to 5/1/2026
ReturnCorrelation
EKSO-47.2% 
Market (SPY)78.7%3.1%
Sector (XLV)14.3%0.8%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
EKSO Return-57%-55%110%-76%-6%39%-87%
Peers Return7%-24%180%29%-17%-8%125%
S&P 500 Return27%-19%24%23%16%5%92%

Monthly Win Rates [3]
EKSO Win Rate8%50%50%8%58%100% 
Peers Win Rate55%50%53%53%37%35% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
EKSO Max Drawdown-57%-61%-44%-77%-97%-9% 
Peers Max Drawdown-11%-43%-19%-15%-33%-15% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-7% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: MYO, ISRG, SYK, ZBH, GMED.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/1/2026 (YTD)

How Low Can It Go

EventEKSOS&P 500
2025 US Tariff Shock
  % Loss-96.7%-18.8%
  % Gain to Breakeven2891.4%23.1%
  Time to Breakeven217 days79 days
2024 Yen Carry Trade Unwind
  % Loss-19.3%-7.8%
  % Gain to Breakeven23.9%8.5%
  Time to Breakeven7 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-47.2%-9.5%
  % Gain to Breakeven89.6%10.5%
  Time to Breakeven37 days24 days
2023 SVB Regional Banking Crisis
  % Loss-28.1%-6.7%
  % Gain to Breakeven39.2%7.1%
  Time to Breakeven161 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-53.1%-24.5%
  % Gain to Breakeven113.2%32.4%
  Time to Breakeven435 days427 days
2020 COVID-19 Crash
  % Loss-54.3%-33.7%
  % Gain to Breakeven118.9%50.9%
  Time to Breakeven91 days140 days

Compare to MYO, ISRG, SYK, ZBH, GMED

In The Past

Ekso Bionics's stock fell -96.7% during the 2025 US Tariff Shock. Such a loss loss requires a 2891.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventEKSOS&P 500
2025 US Tariff Shock
  % Loss-96.7%-18.8%
  % Gain to Breakeven2891.4%23.1%
  Time to Breakeven217 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-47.2%-9.5%
  % Gain to Breakeven89.6%10.5%
  Time to Breakeven37 days24 days
2023 SVB Regional Banking Crisis
  % Loss-28.1%-6.7%
  % Gain to Breakeven39.2%7.1%
  Time to Breakeven161 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-53.1%-24.5%
  % Gain to Breakeven113.2%32.4%
  Time to Breakeven435 days427 days
2020 COVID-19 Crash
  % Loss-54.3%-33.7%
  % Gain to Breakeven118.9%50.9%
  Time to Breakeven91 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-44.4%-19.2%
  % Gain to Breakeven79.8%23.7%
  Time to Breakeven44 days105 days

Compare to MYO, ISRG, SYK, ZBH, GMED

In The Past

Ekso Bionics's stock fell -96.7% during the 2025 US Tariff Shock. Such a loss loss requires a 2891.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Ekso Bionics (EKSO)

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.

AI Analysis | Feedback

Here are a few brief analogies to describe Ekso Bionics:

  • Ekso Bionics is like **Stryker for robotic rehabilitation suits**.
  • Ekso Bionics is like **DeWalt for wearable industrial power tools**.

AI Analysis | Feedback

Here are the major products of Ekso Bionics:

  • EksoNR: A wearable bionic suit and rehabilitation device for treating patients with neurological injuries.
  • EksoUE: A wearable upper extremity assistive device designed to reduce gravity's effect on a wearer's shoulders and arms.
  • EksoWorks Exoskeletons: Devices engineered for able-bodied users to perform repetitive industrial tasks for extended periods.

AI Analysis | Feedback

Ekso Bionics (symbol: EKSO) primarily sells its products to other companies and institutions, rather than directly to individuals. Based on the company description, specific names of its major customer companies are not provided. However, its customers fall into distinct categories aligned with its two operating segments:

EksoHealth Segment Customers:

  • Healthcare Providers and Institutions: This category includes hospitals, rehabilitation centers, and specialized medical clinics that purchase Ekso Bionics' medical exoskeleton devices (like EksoNR and EksoUE). These organizations utilize the devices to assist physical therapists and physicians in the treatment and rehabilitation of patients with neurological and musculoskeletal conditions such as acquired brain injury, stroke, and spinal cord injury.

EksoWorks Segment Customers:

  • Industrial and Manufacturing Companies: Businesses in sectors such as manufacturing, automotive, aerospace, and other industrial applications are customers for EksoWorks' exoskeleton devices. These companies acquire the technology to enable their able-bodied workers to perform strenuous and repetitive tasks for extended periods, aiming to reduce fatigue, prevent injuries, and enhance productivity on the job.
  • Construction, Logistics, and Warehousing Companies: Organizations within these industries also represent a customer base for EksoWorks products. They utilize exoskeletons to support workers engaged in physically demanding roles involving lifting, carrying, and repetitive movements, thereby improving safety and operational efficiency.

AI Analysis | Feedback

null

AI Analysis | Feedback

Scott Davis

Chief Executive Officer

Mr. Davis has served as Chief Executive Officer and a Director of Ekso Bionics since December 2022. He previously held roles as President and Chief Operating Officer from January 2022 to December 2022, and Executive Vice President of Strategy and Corporate Development since April 2021. With over two decades of leadership success in high-tech companies, Mr. Davis’s experience includes serving as Chief Executive Officer of Globalmatix, Inc., an IoT connected telematics solution provider, from December 2018 to March 2021, and SVP Strategy for GetWireless, LLC from January 2017 to December 2018. He also provided C-level consulting services as President of SGD Executive Services LLC from 2015 through 2020. Prior to 2015, he was Vice President of Global Sales Enterprise Solutions for Sierra Wireless, Inc. from 2007.

Jerome Wong

Chief Financial Officer and Corporate Secretary

Mr. Wong has served as Chief Financial Officer and Corporate Secretary since 2022, initially appointed as Interim Chief Financial Officer in May 2022. He first joined Ekso Bionics in 2017 as Corporate Controller. He possesses more than 20 years of experience in finance, accounting, and strategy, particularly within high-technology and life sciences public companies. Before embarking on his corporate career in 2005, Mr. Wong was an Audit Manager at Deloitte & Touche, LLP.

Jason Jones

Chief Operating Officer

Mr. Jones is the Chief Operating Officer of Ekso Bionics. He has dedicated his career to building products, technology, and companies across various sectors, including medical devices, industrial automation, semiconductors, and solar energy.

Stephan Aderhold

Senior Vice President & General Manager EMEA

Mr. Aderhold serves as the Senior Vice President & General Manager for Europe, the Middle East, and Africa (EMEA). He joined Ekso Bionics in 2017 and brings 15 years of experience in medical devices, specifically in areas like eye healthcare and gastroenterology, and is recognized as a team enabler and innovative leader.

Chwee Foon Lim

President, APAC

Ms. Lim is the President for the Asia Pacific (APAC) region at Ekso Bionics.

AI Analysis | Feedback

The key risks to Ekso Bionics (EKSO) include a proposed business combination, the complex reimbursement process for its products, and ongoing profitability challenges.

The most significant risk to Ekso Bionics is its proposed business combination with Applied Digital Corporation's cloud computing business. There is a risk that this transaction may not be completed on the anticipated terms or timeline, or potentially not at all. If the business combination fails, Ekso Bionics anticipates limited liquidity, a potential need for highly dilutive financing, and could face restructuring or even wind-down. The company is currently incurring substantial costs related to this potential transaction, which impacts its liquidity and ability to survive as a standalone entity if the merger is not consummated.

Another key risk involves the complex and lengthy reimbursement process for its products, particularly in the medical markets. Ekso's growth depends heavily on continued support from the Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA). Delays or reversals in reimbursement policies could materially reduce demand for their Personal Health devices. Furthermore, the company must obtain and maintain necessary regulatory clearances and approvals for its medical device products, and failure to comply could lead to sanctions, product recalls, or withdrawal of regulatory approvals.

Finally, Ekso Bionics faces risks related to its profitability and cash burn. The company has incurred significant losses to date and expects continued losses in the future. Its ability to continue as a going concern is uncertain, as it may not have sufficient cash to fund operations for the next 12 months without securing additional capital, especially if the proposed business combination does not close. Future capital raises to address these needs could dilute current shareholders.

AI Analysis | Feedback

null

AI Analysis | Feedback

Ekso Bionics (symbol: EKSO) operates in two primary segments, EksoHealth and EksoWorks, each addressing distinct, growing markets for exoskeleton technology.

EksoHealth Segment (Medical Exoskeletons)

The EksoHealth segment focuses on medical markets, with products such as EksoNR for rehabilitation after acquired brain injury (ABI), stroke, and spinal cord injury (SCI), and EksoUE for upper extremity assistance.

  • The global medical exoskeleton market was valued at approximately USD 653.85 million in 2024 and is projected to reach USD 12,989.81 million by 2032, demonstrating a Compound Annual Growth Rate (CAGR) of 45.30% during the forecast period.
  • Another estimate places the global medical exoskeleton market size at USD 428.4 million in 2023, with an expected growth to USD 4.5 billion by 2032, at a CAGR of 30.6% from 2024–2032.
  • The market for robotic exoskeletons specifically for rehabilitation was valued at USD 1.17 billion globally in 2024 and is anticipated to grow to USD 3.35 billion by 2032, at a CAGR of 14.00%.
  • For medical rehabilitation exoskeletons, the global market size was US$ 158 million in 2025 and is forecast to reach US$ 915 million by 2032 with a CAGR of 29.0% from 2026-2032.
  • North America holds a significant share in the medical exoskeleton market, dominating with an estimated 38% share in 2025. In 2024, North America's medical exoskeleton market accounted for USD 188 million in revenue.
  • Lower body exoskeletons, which include devices like EksoNR used for gait training in stroke and spinal cord injury, held a prominent share of 43.2% in the medical exoskeleton market in 2025. Upper body exoskeletons, such as EksoUE, are projected to grow at a CAGR of 14.1% over the forecast period within the medical exoskeleton market.

EksoWorks Segment (Industrial Exoskeletons)

The EksoWorks segment provides exoskeleton devices for able-bodied users in industrial settings to perform difficult repetitive work.

  • The global industrial exoskeleton market was valued at USD 330 million in 2024 and is projected to reach approximately USD 1.62 billion by 2030, with a CAGR of 30.2%.
  • The industrial and commercial segments collectively account for approximately 85% of the total exoskeleton market.
  • Europe and North America currently lead in the adoption of industrial exoskeletons, with rising demand also noted in the Asia-Pacific region, particularly in the automotive and electronics industries.

Overall Exoskeleton Market

Considering both medical and industrial applications, the broader exoskeleton market demonstrates substantial growth:

  • The global exoskeleton market size was estimated at USD 590.02 million in 2025 and is projected to reach USD 1.79 billion by 2033, growing at a CAGR of 14.48% from 2026 to 2033.
  • Another estimate indicates the global exoskeleton market size was USD 584.5 million in 2025 and is projected to reach USD 2.41 billion by 2035, growing at a CAGR of 17.1% from 2026-2035.
  • The global wearable robotic exoskeleton market size was valued at USD 2.49 billion in 2025 and is projected to grow to USD 64.23 billion by 2034, exhibiting a CAGR of 43.7%.
  • The U.S. exoskeleton market size was estimated at USD 251.5 million in 2025 and is predicted to increase to approximately USD 864.37 million by 2035, expanding at a CAGR of 13.14% from 2026 to 2035.
  • North America is expected to remain the largest regional market, projected to hold a 49.3% share by 2035. The Asia Pacific region is anticipated to be the fastest-growing market.

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Ekso Bionics (EKSO) over the next 2-3 years:

  1. Expansion of the Personal Health Segment through CMS Reimbursement and Strategic Distribution Partnerships: A significant driver is the broadening patient access to the Ekso Indego® Personal device, greatly aided by the Centers for Medicare & Medicaid Services (CMS) approval for reimbursement of $91,000 per device in April 2024. This approval is seen to open a serviceable obtainable market of approximately $2 billion across spinal cord injury and VA populations. The company is actively executing this strategy through partnerships with distributors like National Seating & Mobility and Bionic Prosthetics & Orthotics, aiming to accelerate device placements in 2025–2027.
  2. Bolstering Demand and Innovation within the Enterprise Health Segment: Ekso Bionics plans to further bolster demand for its existing EksoNR device. The company has demonstrated success in driving multi-unit orders from network operators within its EksoHealth business. Innovations, such as the launch of GaitCoach software for EksoNR devices, are also expected to address patient rehabilitation needs and contribute to growth by bringing the latest advancements to their exoskeleton devices.
  3. International Market Expansion in Europe and APAC: Ekso Bionics anticipates continued sales growth through strategic expansion in European and Asia Pacific (APAC) markets. The company sees potential for the Indego Personal product line in these regions, where reimbursement opportunities are emerging.
  4. Growth in the EksoWorks Industrial Segment: The expansion of the EksoWorks segment, which designs, engineers, manufactures, and markets exoskeleton devices for able-bodied users performing difficult repetitive work, represents another strategic approach to revenue growth.

AI Analysis | Feedback

Share Repurchases

  • Ekso Bionics Holdings, Inc. has not reported any issuer purchases of equity securities in their recent annual reports.

Share Issuance

  • Ekso Bionics Holdings, Inc. completed a 1-for-15 reverse stock split on June 2, 2025.
  • The company announced a $3.7 million registered direct offering of common stock on October 29, 2025.
  • Ekso Bionics priced a $5.852 million private placement on January 21, 2026.

Capital Expenditures

  • Capital expenditures in the most recent quarter totaled -$0.126 million.
  • In the last 12 months, capital expenditures were -$188,000.

Better Bets vs. Ekso Bionics (EKSO)

Latest Trefis Analyses

Title
0ARTICLES

Trade Ideas

Select ideas related to EKSO.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
GEHC_4302026_Dip_Buyer_FCFYield04302026GEHCGE HealthCare TechnologiesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
IQV_4302026_Dip_Buyer_FCFYield04302026IQVIQVIADip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
UHS_4302026_Dip_Buyer_FCFYield04302026UHSUniversal Health ServicesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		0.0%0.0%0.0%
ABT_4302026_Dip_Buyer_ValueBuy04302026ABTAbbott LaboratoriesDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.0%0.0%0.0%
ZBIO_4302026_Insider_Buying_45D_2Buy_200K04302026ZBIOZenas BioPharmaInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days		0.0%0.0%0.0%

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

EKSOMYOISRGSYKZBHGMEDMedian
NameEkso Bio.Myomo Intuitiv.Stryker Zimmer B.Globus M. 
Mkt Price11.790.90457.78294.7382.9091.3487.12
Mkt Cap0.00.0162.5112.716.312.314.3
Rev LTM124110,58225,1168,2322,9395,585
Op Inc LTM-16-143,2235,0591,356537947
FCF LTM-12-182,8344,2831,4205791,000
FCF 3Y Avg-11-101,7253,6351,250383817
CFO LTM-12-153,3615,0441,6977531,225
CFO 3Y Avg-11-82,6004,3321,5935061,049

Growth & Margins

EKSOMYOISRGSYKZBHGMEDMedian
NameEkso Bio.Myomo Intuitiv.Stryker Zimmer B.Globus M. 
Rev Chg LTM-34.1%25.7%21.4%11.2%7.2%16.7%13.9%
Rev Chg 3Y Avg-4.1%39.5%18.1%10.8%5.9%43.5%14.5%
Rev Chg Q-36.6%-5.9%23.0%11.4%10.9%25.7%11.2%
QoQ Delta Rev Chg LTM-9.6%-1.7%5.1%3.0%2.8%6.1%2.9%
Op Inc Chg LTM-45.7%-132.0%31.1%8.4%-11.3%144.9%-1.4%
Op Inc Chg 3Y Avg-3.5%-28.2%27.6%17.8%5.3%46.3%11.5%
Op Mgn LTM-134.1%-35.2%30.5%20.1%16.5%18.3%17.4%
Op Mgn 3Y Avg-90.8%-32.3%28.0%20.0%18.7%13.3%16.0%
QoQ Delta Op Mgn LTM-29.9%-6.7%1.2%0.5%-2.2%2.6%-0.8%
CFO/Rev LTM-103.4%-35.5%31.8%20.1%20.6%25.6%20.3%
CFO/Rev 3Y Avg-71.4%-25.9%28.8%19.0%20.5%20.6%19.7%
FCF/Rev LTM-104.9%-43.6%26.8%17.1%17.3%19.7%17.2%
FCF/Rev 3Y Avg-72.2%-30.2%18.3%15.9%16.1%15.4%15.7%

Valuation

EKSOMYOISRGSYKZBHGMEDMedian
NameEkso Bio.Myomo Intuitiv.Stryker Zimmer B.Globus M. 
Mkt Cap0.00.0162.5112.716.312.314.3
P/S3.60.915.44.52.04.23.9
P/Op Inc-2.7-2.650.422.312.022.917.2
P/EBIT-2.7-2.650.422.014.522.918.3
P/E-2.7-2.454.534.723.222.823.0
P/CFO-3.5-2.648.322.49.616.313.0
Total Yield-37.3%-41.0%1.8%4.0%5.5%4.4%2.9%
Dividend Yield0.0%0.0%0.0%1.1%1.2%0.0%0.0%
FCF Yield 3Y Avg-661.5%-17.3%1.0%2.8%6.0%3.6%1.9%
D/E0.10.50.00.10.50.00.1
Net D/E0.00.0-0.00.10.4-0.00.0

Returns

EKSOMYOISRGSYKZBHGMEDMedian
NameEkso Bio.Myomo Intuitiv.Stryker Zimmer B.Globus M. 
1M Rtn10.7%33.3%-1.4%-10.5%-8.9%4.1%1.3%
3M Rtn35.5%7.2%-9.2%-20.0%-4.5%0.7%-1.9%
6M Rtn118.7%-2.8%-14.3%-16.8%-17.1%51.3%-8.6%
12M Rtn62.5%-81.0%-11.5%-20.4%-17.7%28.4%-14.6%
3Y Rtn-45.8%63.2%52.0%3.2%-40.4%61.7%27.6%
1M Excs Rtn0.7%23.3%-11.4%-20.5%-18.9%-5.9%-8.6%
3M Excs Rtn31.3%3.0%-13.4%-24.2%-8.7%-3.5%-6.1%
6M Excs Rtn119.6%-11.7%-19.8%-24.8%-21.3%43.6%-15.7%
12M Excs Rtn36.0%-110.7%-41.1%-50.2%-48.5%-2.6%-44.8%
3Y Excs Rtn-122.1%-27.7%-23.1%-76.7%-117.0%-19.8%-52.2%

Comparison Analyses

null

FDA Approved Drugs Data

Expand for More
Post-Approval Fwd Returns
FDA
App #		Brand
Name		Generic
Name		Dosage
Form		FDA
Approval		3M
Rtn		6M
Rtn		1Y
Rtn		2Y
Rtn		Total
Rtn
NDA208712  VONJOpacritinib citratecapsule2282022-29.2%-9.6%-45.0%-24.2%-69.2%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Single Segment1818   
EksoHealth  12108
EksoWorks  111
Total181813119


Price Behavior

Price Behavior
Market Price$11.79 
Market Cap ($ Bil)0.0 
First Trading Date01/16/2014 
Distance from 52W High-9.0% 
   50 Days200 Days
DMA Price$10.64$6.79
DMA Trendupup
Distance from DMA10.8%73.6%
 3M1YR
Volatility88.1%1,461.1%
Downside Capture0.370.94
Upside Capture175.53180.99
Correlation (SPY)27.4%4.5%
EKSO Betas & Captures as of 4/30/2026

 1M2M3M6M1Y3Y
Beta1.031.251.612.204.991.71
Up Beta2.311.991.271.37-4.81-0.77
Down Beta25.443.243.376.434.381.81
Up Capture20%73%193%322%283%47%
Bmk +ve Days15223166141428
Stock +ve Days14243466130365
Down Capture-775%16%65%61%152%106%
Bmk -ve Days4183056108321
Stock -ve Days7182957118369

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EKSO
EKSO77.4%1,461.0%1.01-
Sector ETF (XLV)5.2%16.0%0.130.3%
Equity (SPY)30.6%12.5%1.884.2%
Gold (GLD)39.5%27.2%1.209.9%
Commodities (DBC)51.5%17.9%2.2011.4%
Real Estate (VNQ)13.1%13.5%0.67-0.0%
Bitcoin (BTCUSD)-18.2%42.1%-0.365.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EKSO
EKSO-32.1%655.6%0.41-
Sector ETF (XLV)5.0%14.6%0.171.1%
Equity (SPY)12.8%17.1%0.593.0%
Gold (GLD)20.5%17.9%0.947.0%
Commodities (DBC)14.3%19.1%0.615.3%
Real Estate (VNQ)3.5%18.8%0.091.1%
Bitcoin (BTCUSD)7.4%56.1%0.352.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with EKSO
EKSO-34.7%477.9%0.30-
Sector ETF (XLV)9.1%16.5%0.452.0%
Equity (SPY)14.9%17.9%0.713.5%
Gold (GLD)13.6%15.9%0.715.7%
Commodities (DBC)9.7%17.7%0.465.0%
Real Estate (VNQ)5.7%20.7%0.241.8%
Bitcoin (BTCUSD)67.4%66.9%1.071.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date4152026
Short Interest: Shares Quantity0.2 Mil
Short Interest: % Change Since 33120269.2%
Average Daily Volume0.1 Mil
Days-to-Cover Short Interest2.3 days
Basic Shares Quantity3.6 Mil
Short % of Basic Shares6.0%

Returns Analyses

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/17/202613.0%7.8%9.2%
10/28/20259.1%6.7%-7.1%
7/28/2025-27.4%-27.4%-17.4%
5/5/2025-9.1%-9.7%-39.0%
1/13/2025-9.7%-17.4%-27.0%
10/28/2024-15.0%-22.9%-40.5%
7/29/2024-28.6%-34.0%-23.9%
4/29/2024-3.9%4.7%-8.1%
...
SUMMARY STATS   
# Positive8138
# Negative14914
Median Positive8.1%6.1%26.8%
Median Negative-9.2%-17.4%-20.5%
Max Positive14.0%65.3%118.7%
Max Negative-28.6%-36.3%-40.5%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202604/28/202610-Q
12/31/202502/23/202610-K
09/30/202510/28/202510-Q
06/30/202507/28/202510-Q
03/31/202505/05/202510-Q
12/31/202403/03/202510-K
09/30/202410/28/202410-Q
06/30/202407/29/202410-Q
03/31/202404/29/202410-Q
12/31/202303/04/202410-K
09/30/202310/26/202310-Q
06/30/202307/27/202310-Q
03/31/202304/27/202310-Q
12/31/202203/28/202310-K
09/30/202211/03/202210-Q
06/30/202207/28/202210-Q

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Jones, Jason CChief Operating Officer401(k)Buy320202611.851,30815,50052,721Form
2Wong, JeromeChief Financial Officer401(k)Buy320202611.851,30815,50049,580Form
3Asher, Daniel by DBA Trading, LLCBuy21920269.601,20011,5202,495,923Form
4Asher, Daniel by DBA Trading, LLCBuy21720269.0427,192245,6872,338,253Form
5Asher, Daniel by DBA Trading, LLCBuy21720269.5739,032373,6562,217,122Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.